Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Announces Quarterly Earnings Results, Misses Estimates By $3.23 EPS

Key Points

• Quarterly results missed earnings estimates: Armata reported a loss of ($3.42) EPS, missing the consensus of ($0.19) by $3.23, while revenue of $1.09 million topped expectations of $0.74 million.
• Stock and valuation snapshot: Shares traded up to $8.61 after the report, the company has a market cap of about $313 million, a 52‑week range of $0.90–$16.34 and a negative PE of -5.31.
• Analyst sentiment is positive: Two analysts have Buy ratings with an average price target of $15.00, including HC Wainwright raising its target to $15 and JonesTrading initiating coverage with a Buy.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($3.42) EPS for the quarter, missing the consensus estimate of ($0.19) by ($3.23), FiscalAI reports. The company had revenue of $1.09 million for the quarter, compared to analysts' expectations of $0.74 million.

Armata Pharmaceuticals Stock Performance

Shares of NYSEAMERICAN ARMP traded up $0.40 during midday trading on Wednesday, reaching $8.61. 35,713 shares of the company's stock were exchanged, compared to its average volume of 48,862. Armata Pharmaceuticals has a 52-week low of $0.90 and a 52-week high of $16.34. The business's fifty day moving average price is $8.59 and its two-hundred day moving average price is $6.37. The stock has a market capitalization of $313.49 million, a PE ratio of -5.31 and a beta of 1.30.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. HC Wainwright raised their target price on shares of Armata Pharmaceuticals from $9.00 to $15.00 and gave the company a "buy" rating in a research note on Monday, February 23rd. JonesTrading began coverage on Armata Pharmaceuticals in a research note on Monday, January 5th. They set a "buy" rating and a $15.00 price objective on the stock. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $15.00.

Hedge Funds Weigh In On Armata Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ARMP. Geode Capital Management LLC grew its position in shares of Armata Pharmaceuticals by 5.1% during the fourth quarter. Geode Capital Management LLC now owns 109,888 shares of the company's stock worth $690,000 after buying an additional 5,342 shares in the last quarter. State Street Corp raised its holdings in Armata Pharmaceuticals by 26.1% in the fourth quarter. State Street Corp now owns 50,800 shares of the company's stock valued at $319,000 after acquiring an additional 10,500 shares in the last quarter. Jane Street Group LLC bought a new position in Armata Pharmaceuticals during the 4th quarter valued at $108,000. Millennium Management LLC bought a new position in Armata Pharmaceuticals during the 4th quarter valued at $164,000. Finally, Renaissance Technologies LLC grew its holdings in Armata Pharmaceuticals by 65.9% during the 4th quarter. Renaissance Technologies LLC now owns 68,496 shares of the company's stock worth $430,000 after acquiring an additional 27,200 shares in the last quarter. 3.57% of the stock is owned by institutional investors and hedge funds.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company's proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata's pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.